Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 1/20 | 0.48 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17552982 | 0.91 | FASN (0.48) | FASNDGAT1CHRM2CYP2C9ALDH1A1 | |
| SCHEMBL10550528 | 0.91 | FASN (0.48) | FASNDGAT1CHRM2CYP2C9ALDH1A1 | |
| SCHEMBL18156625 | 0.89 | FASN (0.39) | FASNDGAT1CHRM2SLC6A4SLC6A3 | |
| SCHEMBL14621251 | 0.88 | FASN (0.48) | FASNDGAT1CHRM2CYP2C9ALDH1A1 | |
| SCHEMBL15744345 | 0.87 | FASN (0.47) | FASNDGAT1CHRM2CYP2C9 | |
| SCHEMBL16591211 | 0.86 | FASN (0.51) | FASNDGAT1CHRM2CYP2C9ALDH1A1 | |
| SCHEMBL12930554 | 0.86 | FASN (0.51) | FASNDGAT1CHRM2CYP2C9ALDH1A1 | |
| SCHEMBL10555297 | 0.86 | FASN (0.43) | FASNCYP2C9ALDH1A1LMNAMAPT | |
| SCHEMBL30332320 | 0.86 | FASN (0.37) | FASNCYP2C9 | |
| SCHEMBL18418532 | 0.85 | FASN (0.46) | FASNDGAT1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3081621-B1 | LIQUID CRYSTAL DISPLAY DEVICE AND LIQUID CRYSTAL COMPOSITION USED THEREFOR | SAMSUNG DISPLAY CO LTD (KR) | 2019-06-12 | — | — | EP | disclosed |
| US-20170349831-A1 | LIQUID CRYSTAL COMPOUND CONTAINING DIFLUORMETHOXY BRIDGE, COMPOSITION AND APPLICATION THEREOF | BEIJING BAYI SPACE LCD TECHNOLOGY CO., LTD. (CN) | 2017-12-07 | — | — | US | disclosed |
| US-20170349831-A1 | LIQUID CRYSTAL COMPOUND CONTAINING DIFLUORMETHOXY BRIDGE, COMPOSITION AND APPLICATION THEREOF | BEIJING BAYI SPACE LCD TECHNOLOGY CO., LTD. (CN) | 2017-12-07 | — | — | US | disclosed |
| US-9783735-B2 | Liquid crystal display device and liquid crystal composition used therefor | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-10-10 | — | — | US | disclosed |
| US-9783735-B2 | Liquid crystal display device and liquid crystal composition used therefor | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-10-10 | — | — | US | disclosed |
| EP-3222696-A2 | LIQUID CRYSTAL DISPLAY DEVICE AND LIQUID CRYSTAL COMPOSITION USED THEREFOR | Samsung Display Co., Ltd. (KR) | 2017-09-27 | — | — | EP | disclosed |
| US-20160304783-A1 | LIQUID CRYSTAL DISPLAY DEVICE AND LIQUID CRYSTAL COMPOSITION USED THEREFOR | DONGJIN SEMICHEM CO., LTD. (KR) | 2016-10-20 | — | — | US | disclosed |
| US-20160304783-A1 | LIQUID CRYSTAL DISPLAY DEVICE AND LIQUID CRYSTAL COMPOSITION USED THEREFOR | DONGJIN SEMICHEM CO., LTD. (KR) | 2016-10-20 | — | — | US | disclosed |
| EP-3081621-A2 | LIQUID CRYSTAL DISPLAY DEVICE AND LIQUID CRYSTAL COMPOSITION USED THEREFOR | Samsung Display Co., Ltd. (KR) | 2016-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304783-A1 | LIQUID CRYSTAL DISPLAY DEVICE AND LIQUID CRYSTAL COMPOSITION USED THEREFOR | SLC39A11, CYP4F11, WEE1 | FASN 2164/4885DGAT1 1761/4885CHRM2 1835/4885 |
| US-20170349831-A1 | LIQUID CRYSTAL COMPOUND CONTAINING DIFLUORMETHOXY BRIDGE, COMPOSITION AND APPLICATION THEREOF | PLD1, CCND1, LPCAT1 | FASN 1358/4885DGAT1 283/4885CHRM2 1179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.